Cipla is on track to launch key products, such as gAdvair, gAbraxane, gRevlimid and three peptide products over FY23-24, it said, adding that the US sales run-rate will improve from H2FY23, and barring COVID-19, sales performance in India continues to be robust. The brokerage firm expects a revenue CAGR of 13 per cent, an EBITDA CAGR of 21 per cent and a PAT CAGR of 28 per cent over FY22-24E.
Fed’s Waller, leaning against March cut, sees easings later in year
Federal Reserve Governor Christopher Waller opposes a rate cut at the upcoming policy meeting. He suggests future cuts are possible if inflation pressures decrease. Waller
March 7, 2025